Our scientists and executives have played key roles in the discovery, development and commercialization of some of the world’s most widely used medicines. Our unique experience gained from leading pharmaceutical organizations and drug development teams provides a strong platform for growth and, together with our well-established network in the liver and GI areas, positions us well for success.
President and Chief Executive Officer
Ron Cooper, Albireo’s first President and CEO is a global P&L leader with a track record of growing businesses, brands and organizations in the U.S. and Europe. For over 25 years, Ron worked in five different countries and held positions of increasing responsibility in sales, marketing and general management with Bristol-Myers Squibb, culminating in his role as President of Europe where he was responsible for over 30 countries with sales exceeding $4.5 billion.
While at BMS, Ron played a leadership role in several product successes, including Abilify®, Avapro®, Atripla®, Eliquis®, Orencia®, Pravachol®, Plavix®, Reyataz® Sustiva® Sprycel® and Yervoy®. Ron has successfully completed over a dozen business development deals, including the creation of the first single tablet HIV/AIDS regimen partnership. He is a graduate of St. Francis Xavier University in Canada.
Martha (Muffy) Carter
Chief Regulatory Officer
Martha (Muffy) Carter joined Albireo in November 2016. Muffy has four decades of regulatory experience in the biopharmaceutical industry. Most recently, Muffy was Chief Regulatory Officer and Senior Vice President of Aegerion Pharmaceuticals, a biopharmaceutical company focused in rare diseases, where she established global regulatory and quality functions and played a key role in bringing JUXTAPID®/LOJUXTA® (lomitapide) for the treatment of homozygous familial hypercholesterolemia to market in 36 countries. Prior to Aegerion, she served as Senior Vice President and Chief Regulatory Officer at Proteon Therapeutics and Senior Vice President, Regulatory Affairs at Trine Pharmaceuticals. Earlier in her career, Muffy held various positions of increasing responsibility in regulatory affairs, strategic planning and compliance. She has authored and co-authored numerous publications on regulatory matters and professional ethics. Muffy holds a B.A. in biology from Northeastern University.
Jan Mattsson, Ph.D.
Chief Operating Officer and Co-Founder
Jan Mattsson has plus 20 years of experience in the pharmaceutical industry, covering a range of functions including R&D, business development, R&D operations and management. Prior to co-founding Albireo, he held various project leader and management positions at AstraZeneca, primarily in gastrointestinal R&D. Jan holds a B.Sc. in Chemistry and a Ph.D. in Biochemistry from University of Gothenburg.
Chief Financial Officer
Tom Shea joined Albireo in July 2016 as Chief Financial Officer. Previously, he served Executive Vice President and Chief Financial Officer of Epirus Biopharmaceuticals, a multinational biosimilar Company. Prior to Epirus, Tom served as the Chief Financial Officer of a number of biopharmaceutical companies, including Tolerx and sister companies Euthymics, Neurovance, EBI Life Sciences. Formerly, he was Chief Financial Officer at Cubist Pharmaceuticals (acquired by Merck) where he was one of the Company’s initial employees and served for 10 years, playing a leadership role in Cubist’s successful initial public offering.
Paresh Soni, M.D., Ph.D.
Chief Medical Officer
Paresh Soni joined Albireo in September 2016 as Chief Medical Officer. Paresh has more than 25 years of clinical drug development and academic medical experience. Most recently, he served as Vice President, Global Medical Sciences at Alexion Pharmaceuticals, a global rare disease biopharma company. Prior to Alexion, Paresh served as Senior Vice President, Head of Development at Amarin Corporation where he was responsible for the development and regulatory approval of Vascepa® for elevated triglycerides. He began his pharmaceutical career at Pfizer, holding various positions of increasing responsibility. Paresh is an internist and gastroenterologist, who completed his medical training at the University of Natal in South Africa and a research fellowship at the Division of Hepatology, Royal Free Hospital School of Medicine, London. He has authored or co-authored more than 50 scientific papers in peer-reviewed journals, in addition to numerous abstracts.
Chief Corporate Officer
Pete Zorn joined Albireo in 2015 as Senior Vice President, Corporate Development and General Counsel, becoming Chief Corporate Officer in January 2017. Previously, he was General Counsel and Vice President, Communications at Santaris Pharma, a Denmark-headquartered company acquired by Roche in 2014. Prior to Santaris, Pete served for 11 years as General Counsel at Targacept, Inc. where he played a leadership role in a variety of significant milestones, including its company-launching spinout, IPO and additional financings, and multiple complex collaborations with major pharmaceutical companies. Pete began his career as a corporate attorney at a large law firm. He received his undergraduate degree from Harvard and his J.D. from the University of North Carolina at Chapel Hill.
Per-Göran Gillberg, Ph.D., Prof.
Vice President, Development and Co-Founder
Per-Göran Gillberg has proven expertise and a track record of success in the Swedish pharmaceutical industry, with over 25 years of experience at Pharmacia, Kabi and AstraZeneca. He has industry experience covering drug discovery and development through to marketed products. In particular, he played an instrumental role in the preclinical and clinical development of tolterodine, a marketed treatment for urinary incontinence.
Kristina Torfgård, Ph.D.
Vice President, Clinical and Regulatory Affairs
Kristina Torfgård has more than 20 years of experience in drug development covering the full product lifecycle and spanning multiple therapeutic and disease areas, including gastrointestinal, neuroscience, cardiovascular and metabolic disease/diabetes. Prior to joining Albireo, Kristina was with AstraZeneca, where she worked for several years in the clinical organization in various senior and global leadership roles. In particular, at different times she was responsible for the gastrointestinal portfolio through Phase 2, responsible for the Established Cardiovascular Brands portfolio and led in-licencing projects and scientific collaborations. Kristina holds a. M.Sc. in Pharmacy and a Ph.D. in Clinical Pharmacology.